{
}
UBS AG has maintained a "Buy" rating for Merck KGaA, setting a target price of 180 euros, following the company's planned acquisition of Springworks, which aligns with its strategic goals. Merck shares rose 0.7% to EUR 120.60, indicating a 49.25% upside potential, despite a 13.8% decline since the start of 2025.
UBS AG maintains a "Buy" rating for Roche shares with a target price of 338 francs, following a strong first quarter where sales exceeded estimates by 2%. The share price rose 0.2% to CHF 258.70, indicating a potential upside of 30.65%. Roche's production capacity expansion in the USA is viewed positively amid import tariff concerns.
UBS has maintained a "Buy" rating for Roche, setting a target price of 338 francs following the company's first-quarter results, which surpassed sales expectations by 2%. Analyst Matthew Weston highlighted the positive impact of Roche's increased production capacities in the U.S. amid import tariffs.
UBS AG has maintained a "Neutral" rating for Sartorius vz shares, setting a target price of 302 euros, following positive first-quarter figures, particularly in the bioprocess technology segment. The share price rose 3.3% to EUR 200.60, indicating a potential upside of 50.55% relative to the target. However, the stock has seen a decline of 6.5% since the start of 2025, with Q1 2025 financial results expected on April 16, 2025.
Deutsche Bank has raised its price target for Novartis shares to CHF115 from CHF110, maintaining a Buy rating, driven by optimism surrounding the cancer treatment Pluvicto's label expansion. The company shows strong financial health with a 10.85% revenue growth and a gross profit margin of 75.22%. In contrast, UBS downgraded Novartis from Buy to Neutral, lowering the target to CHF104, citing concerns over upcoming patent expirations that may hinder growth.
UBS has maintained its "Buy" rating for Astrazeneca, setting a target price of 14,200 pence. Analyst Matthew Weston highlighted promising study results for the cholesterol-lowering drug AZD0780 presented at the US Cardiologists Congress.
UBS has maintained a "Buy" rating for AstraZeneca with a target price of 14,200 pence. Analyst Matthew Weston advised caution regarding the Calypso study results for Enebo, a treatment for hypothyroidism, noting the absence of a "clinically significant" designation for the primary endpoint and lack of independent expert commentary, suggesting unmet competitive expectations.
UBS AG has maintained a "Buy" rating on Roche shares with a target price of 338 francs, highlighting the company's partnership with Zealand Pharma for the obesity treatment Petrelintide. Analyst Matthew Weston noted Roche's commitment to expanding obesity treatment mechanisms, following its acquisition of a GLP1/GIP treatment. Roche shares rose 5.3% to CHF 312.10, indicating an 8.3% upside potential from the target price, with a 22.2% increase since the start of 2025.
UBS AG has downgraded its price target for Merck KGaA from €190 to €180 while maintaining a "Buy" rating. Following this analysis, Merck's share price fell by 4.1% to €135.50, reflecting a 32.84% upside potential relative to the new target. Year-to-date, the stock has decreased by 3.1%.
UBS has maintained a "Buy" rating for Merck KGaA but reduced its target price from €190 to €180, citing cautious expectations for Electronics sales and Life Science margins. Following this announcement, Merck shares fell by 4.1% to €135.50, indicating a potential growth of 32.84% relative to the new target.
Matthew Weston
People
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
ubs maintains buy rating for merck shares with target price of 180 euros
12:19 25.04.2025
ubs maintains buy rating for roche with positive sales outlook
14:58 24.04.2025
ubs maintains buy rating for roche with target price of 338 francs
13:40 24.04.2025
ubs maintains neutral rating for sartorius with target price of 302 euros
13:58 19.04.2025
Deutsche Bank raises Novartis price target amid Pluvicto optimism
13:47 03.04.2025
ubs maintains buy rating for astrazeneca with target price of 14200 pence
10:50 01.04.2025
ubs maintains buy rating for astrazeneca amid cautious study results
12:47 17.03.2025
ubs rates roche shares buy with target price of 338 francs
17:03 14.03.2025
ubs lowers merck price target but maintains buy rating
18:57 07.03.2025
UBS maintains buy rating on Merck despite lowering price target to 180 euros
13:26 07.03.2025
Trending
Subcategory
Corporate News
Industry Trends
Stock Market Updates
Retail and Consumer Goods
Global Financial Events
Finance Mergers & Acquisitions
Global Trade Developments
Industry Mergers & Acquisitions
Central Bank Actions
CEO Changes
Banking Regulations
Supply Chain Management
Startups & Entrepreneurship
Energy Sector Developments
Government Economic Policies
Workplace Trends
AI Innovations
Cryptocurrency Trends
Market Analysis and Predictions
Financial Scams and Security
Countries:
Companies:
The Goldman Sachs Group, Inc.
Bank of America Corporation
Apple Inc.
Alphabet Inc.
Barclays PLC
Tesla, Inc.
Wells Fargo & Company
Citigroup Inc.
Deutsche Bank RV Global PP
Commerzbank AG
Lloyds Banking Group plc
PepsiCo, Inc.
BNP Paribas SA
Google Inc.
NVIDIA Corporation
UBS Group AG
Wix.com Ltd.
BP Castrol K.K.
Valvoline Inc.
Bosch Limited
Currencies:
United States Dollar
Euro
Chinese Yuan
British Pound Sterling
Swiss Franc
Indian Rupee
Japanese Yen
Indonesian Rupiah
Canadian Dollar
Russian Ruble
South Korean Won
United Arab Emirates Dirham
Offshore Chinese Yuan
Ghanaian Cedi
Hungarian Forint
Albanian Lek
Brazilian Real
Singapore Dollar
Qatari Riyal
Jordanian Dinar
People:
Donald Trump
Elon Musk
Warren Buffett
Sergey Brin
Larry Page
Goldman Sachs
Kelvin Taylor
Carsten Fritsch
Christopher Chandler
Scott Bessent
Martin Schlegel
Jerome Powell
Kubra Khan
Joe Biden
Volkmar Baur
Christopher Wallerstedt
Brian Moynihan
Airlangga Hartarto
Francesco Gaetano Caltagirone
Leonardo Del Vecchio